港股異動丨開拓藥業暴跌40%,創歷史新低
開拓藥業-B(9939.HK)一度暴跌40%至2.01港元,股價創歷史新低。消息面上,公司公佈KX-826外用治療男性雄激素性脱髮(AGA)的中國III期臨牀試驗已讀出頂線數據。分析結果顯示,該試驗整體安全性優良,KX-826展示了極佳的安全性能,試驗過程未報吿任何重大不良反應。治療24周後,KX-826組TAHC結果顯示,KX-826與基線相比促進了毛髮生長,具有統計學意義(P<0.0001)。與安慰劑相比,KX-826組TAHC在各個訪視點均有提高,差異在統計學上未達到顯著性,但顯示療效趨勢。公司將繼續分析該項III期臨牀試驗的結果,並開展KX-826外用治療脱髮及痤瘡的多項臨牀試驗,持續探索KX-826上市的可能性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.